The goal of this clinical trial is to see if a sleep medication, daridorexant (DTX), can help decrease drinking in people who have alcohol use disorder (AUD) and insomnia.
The main questions it aims to answer are:
* Can DTX decrease alcohol use in individuals with insomnia better than placebo?
* Can DTX increase sleep time and other sleep related outcomes better than placebo?
Participants will:
* Take prescribed medication (DTX or Placebo based on which group they are randomized to).
* Provide urine, breath, saliva, and blood samples.
* Come in for bi-weekly (once every 2 weeks) in-person visits.
* Answer questionnaires and surveys related to sleep, substance use, and physical/mental health.
* Use an EEG headband to track brain activity at night.
* Come in for 3 follow up visits one month, six months, and one year after treatment.